Are environmental interventions (optimal CV control, diet, physical activity, etc.) likely to change the frequency and by how much? Kristine Yaffe, UK
10:55-11:20
Discussion
11:20-11:50
What can pathology contribute to our understanding, given that autopsies come very late in the disease course and show mixed pathology in most cases? Lea Grinberg, Brazil/USA
11:50-12:15
Discussion
12:15-13:15
Industry Symposium
13:15-14:15
Lunch Break
13:15-14:15
Meet the Expert
14:15-15:45
SECTION TITLE
14:15-14:45
Are amyloid and tau dead horses in sporadic, late onset AD, given the disappointments with interventions that were successful in eliminating amyloid yet without clinical benefit? David Knopman, USA
14:45-15:00
Discussion
15:00-15:30
To Futility or Not – When and How Should you Apply Futility Analysis Rema Raman, USA
15:30-15:45
Discussion
15:45-16:00
Coffee Break
16:00-19:00
SECTION TITLE
16:00-16:30
Is APOE4 a potential treatment target, given that we do not understand its mechanism? Daniel Michaelson, Israel
16:30-16:45
Discussion
16:45-17:15
Is neuroinflammation a useful potential therapeutic target? Michael Heneka, Germany
17:15-17:30
Discussion
17:30-18:00
Fear and loathing in recent Alzheimer trials: Aducanumab, albumin/IVIG exchange, and oligomanurate
18:00-18:15
Discussion
18:15-18:45
The need for multiple targets, outcomes, and approaches Vladimir Hachinski, Canada
